- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02455245
A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma
A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Low grade gliomas are the most common central nervous system (CNS) tumors in the pediatric population. They consist of a heterogeneous group of tumors that are classified as World Health Organization (WHO) grade I or II. This includes astrocytic, oligodendroglial, neuronal and mixed glial- neuronal tumors. The clinical behavior of these tumors varies according to location and histology. The cerebellum is the most common location for low grade gliomas, but they can also arise in the cerebrum, deep midline structures such as the hypothalamus, optic pathway and, less frequently, in the brainstem.
Although the etiology of most childhood LGG is unknown, patients with Neurofibromatosis type 1 (NF-1) are one rare group predisposed to developing CNS tumors. NF-1 is an inherited disorder that affects the nervous system, eyes and skin. In addition, children are at an increased risk for developing optic pathway and hypothalamic low grade gliomas. Fifteen to-20% of NF-1 patients will develop these tumors, and they account for up to 70% of the tumors seen in this location. In half of patients with NF-1 and an optic pathway tumor, the patients are not symptomatic and the mass is found incidentally. Many optic gliomas in NF-1 patients follow an indolent course and stabilize without intervention. Patients are most commonly treated when there is deterioration in their vision or a symptomatic increase in the tumor size. Although the event free survival (EFS) has been reported to be similar between NF1 and non-NF1 patients, overall survival is higher in NF1 patients.
Location, as it affects the extent of surgical resection, plays a key role in the prognosis of all patients with low grade gliomas. Complete surgical resection offers a 90% survival rate at 10 years with often no need for adjuvant chemotherapy or radiation. Unfortunately, a gross total resection is not always possible due to the location of the tumor and its proximity to vital structures in the brain. In patients with an incomplete resection, the 10 year EFS is up to 74% with radiation treatment. However, toxicity from radiation, especially in young children, is significant and includes neurocognitive delays, endocrinopathies, secondary malignancy, ototoxicity and vasculopathy. Therefore, most experts agree that the standard of care in young children is to treat low grade gliomas that require adjuvant therapy after surgical resection/biopsy, or whose tumors are not surgically resectable with chemotherapy first, in order to delay or avoid radiation. This is especially true in children with NF-1, where the risk of a secondary malignancy after radiation therapy can be as high as 50% in the lifetime of the child.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Recruiting
- Phoenix Children's Hospital
-
Contact:
- Amy Rosenfield, MD
-
Contact:
- Courtney Hemphill
- Phone Number: 602.933.4649
- Email: Chemphill@phoenixchildrens.com
-
-
California
-
San Diego, California, United States, 92123
- Not yet recruiting
- Rady Children's Hospital
-
Contact:
- John Crawford, MD
-
Contact:
- Mehrzad Milburn, RN, BSN, CCRC
- Phone Number: 858.966.8155
- Email: mmilburn@rchsd.org
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Recruiting
- Yale University
-
Contact:
- Asher M Marks, MD
-
Contact:
- Jennifer Paquette, RN, BSN
- Phone Number: 203.785.5505
- Email: jennifer.paquette@yale.edu
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Ann & Robert H. Lurie Children's Hosptial of Chicago
-
Contact:
- Kevin Ritt
- Phone Number: 312.227.4861
- Email: kritt@luriechildrens.org
-
Contact:
- Laura Kane
- Phone Number: 312-227-4860
- Email: lakane@luriechildrens.org
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Recruiting
- St. Vincent Peyton Manning Children's Hospital
-
Contact:
- Jessica Goodman, MD
-
Contact:
- Rachael Limbach, LPN
- Phone Number: 317.338.9825
- Email: Rachael.Limbach@stvincent.org
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- The Johns Hopkins Hospital
-
Contact:
- Ken Cohen, MD
-
Contact:
- Tammy Scott, RN, OCN
- Phone Number: 410.614.5990
- Email: scottta@jhmi.edu
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Dana-Farber Cancer Institute
-
Contact:
- Mark W Kieran, MD
-
Contact:
- Lianne Greenspan
- Phone Number: 617.632.6740
- Email: Lianne_Greenspan@DFCI.HARVARD.EDU
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Recruiting
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Contact:
- Anne E Bendel, MD
-
Contact:
- Michelle Allard
- Phone Number: 612.813.5913
- Email: Michelle.Allard@childrensmn.org
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Recruiting
- Nationwide Children's Hospital
-
Contact:
- Diana S Osorio, MD
-
Contact:
- Bridget Hoskins, CRA
- Phone Number: 614.722.3654
- Email: bridget.hoskins@nationwidechildrens.org
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Recruiting
- American Family Children's Hospital
-
Contact:
- Neha Patel, MD
- Phone Number: 608-263-6200
-
Contact:
- Jenny Weiland, CCRP, MT
- Phone Number: 608.890.8070
- Email: jlweiland@pediatrics.wisc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Tumor Diagnosis: Low grade gliomas
- Patients must be less than 21 years of age at study entry.
- Central nervous system tumor. Patients with primary spinal cord lesions. Patients with metastatic disease are also allowed.
- No previous therapy for the tumor with the exception of corticosteroids and surgery.
- Performance status:Karnofsky Performance Scale (KPS for > 16 yrs of age) or Lansky Performance Score (LPS for ≤ 16 years of age) ≥ 50 assessed within two weeks prior to registration
- Seizure disorder should be well controlled.
- Normal organ and marrow function
- Female patients of childbearing potential must not be pregnant or breast-feeding. Female patients who have menstruated and are of childbearing potential must have a negative serum or urine pregnancy test prior to enrollment.
- Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 6 months after the last drug administration.
- Ability of subject or parent/guardian to understand and the willingness to sign a written informed consent/assent document. Informed consent/assent must be signed prior to registration on this study.
- Tissue blocks or slides must be sent. If tissue is unavailable, the study chair must be notified prior to enrollment.
Exclusion Criteria:
- Patients who are receiving any other investigational or chemotherapeutic agents will be excluded.
- Patients with known inability to return for follow-up visits or obtain follow-up studies required to assess for toxicity to therapy.
- Patients with Subepenydmal Giant Cell Astrocytomas are excluded. Patients with intrinsic brainstem tumors of the pons will be excluded from the study.
- History of hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to platinum based chemotherapy.
- Patients with uncontrolled inter-current illness are excluded.
- Females who are pregnant or breast feeding are excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Carboplatine and Vincristine
Induction: 10 weeks of Carboplatin and Vincristine therapy. Carboplatin 175 mg/m2 give an an IV infusion weeks 1, 2, 3, 4, 7, 8, 9, 10. Vincristine 1.5mg/m2 (0.05 mg/kg if child less than 12 kg) (maximum dose 2.0 mg) give as an IV bolus infusion on weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. Maintenance: Maintenance consists of 8, 6-week cycles of chemotherapy. It begins week 12 of Induction or when peripheral counts recover with ANC >1,000/µL and platelet count >100,000/µL. Each cycle will consist of 4 weekly doses of carboplatin, three weekly doses of vincristine (given concomitantly with the first 3 weeks of carboplatin), followed by two weeks of rest for a total of 6 weeks. Maintenance will continue for a total of 8 cycles. Carboplatin 175 mg/m2 as an IV continuous infusion over 60 minutes on Week 1, 2, 3, 4 of each cycle. Vincristine 1.5 mg/m2 (0.05 mg/ kg for children <12 kg) (maximum dose 2.0 mg) IV bolus infusion on Week 1, 2, 3 of each cycle. |
|
EXPERIMENTAL: Carboplatin alone
Carboplatin is given once every four weeks, Each 4-week period is considered a cycle. Regimen B will last for 13 cycles which is equivalent to one year (52 weeks). Carboplatin 560 mg/m2 (or 19 mg/kg for children weighing less than 12 kg) IV over 1 hour every 4 weeks |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-free survival
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants who experience improved quality of life as assessed by a Quality of Life questionnaire.
Time Frame: week-6, week-12, month-6, month-12
|
week-6, week-12, month-6, month-12
|
Tumor response rate of each regimen, assessed by magnetic resonance imaging (MRI)
Time Frame: 3 years
|
3 years
|
Number of participants who experience toxicity on each regimen
Time Frame: 3 years
|
3 years
|
Number of B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutations that have an association with clinical outcomes.
Time Frame: 3 years
|
3 years
|
Number of aberrations found through whole exome and ribonucleic acid (RNA) sequencing that coordinate with a clinical outcome.
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Natasha Pillay Smiley, DO, Attending
Publications and helpful links
General Publications
- Gururangan S, Cavazos CM, Ashley D, Herndon JE 2nd, Bruggers CS, Moghrabi A, Scarcella DL, Watral M, Tourt-Uhlig S, Reardon D, Friedman HS. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol. 2002 Jul 1;20(13):2951-8. doi: 10.1200/JCO.2002.12.008.
- Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol. 2009 Nov;24(11):1397-408. doi: 10.1177/0883073809342005.
- Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME, Evans DG. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol. 2006 Jun 1;24(16):2570-5. doi: 10.1200/JCO.2005.03.8349.
- Petronio J, Edwards MS, Prados M, Freyberger S, Rabbitt J, Silver P, Levin VA. Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. J Neurosurg. 1991 May;74(5):701-8. doi: 10.3171/jns.1991.74.5.0701.
- Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, Prados M, Jakacki R, Reaman G, Needles MN, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993 May;11(5):850-6. doi: 10.1200/JCO.1993.11.5.850.
- Lafay-Cousin L, Sung L, Carret AS, Hukin J, Wilson B, Johnston DL, Zelcer S, Silva M, Odame I, Mpofu C, Strother D, Bouffet E. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience. Cancer. 2008 Feb 15;112(4):892-9. doi: 10.1002/cncr.23249.
- Korinthenberg R, Neuburger D, Nikkhah G, Teske C, Schnabel K, Calaminus G. Assessing quality of life in long-term survivors after (1)(2)(5)I brachytherapy for low-grade glioma in childhood. Neuropediatrics. 2011 Jun;42(3):110-5. doi: 10.1055/s-0031-1283111. Epub 2011 Jul 7.
- Bryant R. Managing side effects of childhood cancer treatment. J Pediatr Nurs. 2003 Apr;18(2):113-25. doi: 10.1053/jpdn.2003.11.
- Woodgate RL, Degner LF, Yanofsky R. A different perspective to approaching cancer symptoms in children. J Pain Symptom Manage. 2003 Sep;26(3):800-17. doi: 10.1016/s0885-3924(03)00285-9.
- Kazak AE, Simms S, Rourke MT. Family systems practice in pediatric psychology. J Pediatr Psychol. 2002 Mar;27(2):133-43. doi: 10.1093/jpepsy/27.2.133.
- Mulhern RK, Carpentieri S, Shema S, Stone P, Fairclough D. Factors associated with social and behavioral problems among children recently diagnosed with brain tumor. J Pediatr Psychol. 1993 Jun;18(3):339-50. doi: 10.1093/jpepsy/18.3.339.
- Katz ER, Varni JW. Social support and social cognitive problem-solving in children with newly diagnosed cancer. Cancer. 1993 May 15;71(10 Suppl):3314-9. doi: 10.1002/1097-0142(19930515)71:10+3.0.co;2-1.
- O'Malley JE, Koocher G, Foster D, Slavin L. Psychiatric sequelae of surviving childhood cancer. Am J Orthopsychiatry. 1979 Oct;49(4):608-616. doi: 10.1111/j.1939-0025.1979.tb02646.x.
- Vannatta K, Gartstein MA, Short A, Noll RB. A controlled study of peer relationships of children surviving brain tumors: teacher, peer, and self ratings. J Pediatr Psychol. 1998 Oct;23(5):279-87. doi: 10.1093/jpepsy/23.5.279.
- Lavigne JV, Faier-Routman J. Psychological adjustment to pediatric physical disorders: a meta-analytic review. J Pediatr Psychol. 1992 Apr;17(2):133-57. doi: 10.1093/jpepsy/17.2.133.
- Patenaude AF, Kupst MJ. Psychosocial functioning in pediatric cancer. J Pediatr Psychol. 2005 Jan-Feb;30(1):9-27. doi: 10.1093/jpepsy/jsi012.
- Dolgin MJ, Somer E, Buchvald E, Zaizov R. Quality of life in adult survivors of childhood cancer. Soc Work Health Care. 1999;28(4):31-43. doi: 10.1300/J010v28n04_03.
- Oeffinger KC, Robison LL. Childhood cancer survivors, late effects, and a new model for understanding survivorship. JAMA. 2007 Jun 27;297(24):2762-4. doi: 10.1001/jama.297.24.2762. No abstract available.
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Carboplatin
- Vincristine
Other Study ID Numbers
- LGG 14C03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Grade Glioma
-
St. Jude Children's Research HospitalSpringWorks Therapeutics, Inc.RecruitingLow-Grade Glioma | Recurrent Low-Grade Glioma | Progressive Low-Grade GliomaUnited States
-
National Cancer Institute (NCI)RecruitingLow Grade Glioma | Low Grade Astrocytoma | Metastatic Low Grade Astrocytoma | Metastatic Low Grade GliomaUnited States, Canada, Puerto Rico
-
National Cancer Institute (NCI)RecruitingRecurrent WHO Grade 2 Glioma | Recurrent Low Grade Astrocytoma | Refractory Low Grade Astrocytoma | Refractory Low Grade Glioma | Refractory WHO Grade 1 GliomaUnited States, Canada
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationNot yet recruitingGlioma | Low-grade Glioma | Glioma, Malignant | Low Grade Glioma of Brain | Glioma IntracranialUnited States
-
Neurological Associates of West Los AngelesEnrolling by invitationLow Grade Glioma of BrainUnited States
-
National Cancer Institute (NCI)RecruitingGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States
-
Maastricht Radiation OncologyMaastricht University Medical Center; Ziekenhuis Oost-Limburg; Zuyderland Medisch...Active, not recruitingHigh Grade Glioma | Low-grade GliomaNetherlands
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II GliomaUnited States
-
Hospital del Río HortegaCompletedGlioma | Glioblastoma | Low-grade Glioma | Glioma, Malignant | High-grade GliomaSpain
-
Massachusetts General HospitalNational Cancer Institute (NCI)Active, not recruitingLow Grade Glioma | WHO Grade 3 Glioma With IDH1 Mutation | WHO Grade 3 Glioma With 1p/19q CodeletionUnited States
Clinical Trials on Vincristine
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); Spectrum Pharmaceuticals, IncTerminatedVincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaUnited States
-
ECOG-ACRIN Cancer Research GroupRecruitingRecurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Lymphoblasts 5 Percent or More of Bone Marrow Nucleated CellsUnited States
-
Centre Oscar LambretSFCECompleted
-
M.D. Anderson Cancer CenterInex PharmaceuticalsCompletedSoft Tissue Sarcoma | Lymphoma | Leukemia | Osteosarcoma | Wilms' TumorUnited States
-
Nanjing Luye Sike Pharmaceutical Co., Ltd.China Medical University, China; Xijing Hospital; The Second Hospital of Hebei... and other collaboratorsUnknownAdult Acute Lymphoblastic LeukemiaChina
-
Spectrum Pharmaceuticals, IncParexelCompletedAcute Lymphoblastic Leukemia (ALL)United States, Canada, Germany, Israel, United Kingdom
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedIntraocular RetinoblastomaUnited States, Canada, Australia, New Zealand, India
-
Spectrum Pharmaceuticals, IncTerminatedAcute Lymphoblastic Leukemia (ALL)United States
-
Dartmouth-Hitchcock Medical CenterTerminatedChronic Lymphocytic Leukemia (CLL)United States
-
Inex PharmaceuticalsCompletedLymphomaUnited States, Canada